Skip to main content
. Author manuscript; available in PMC: 2013 Dec 15.
Published in final edited form as: Clin Cancer Res. 2012 Oct 23;18(24):6784–6791. doi: 10.1158/1078-0432.CCR-12-1785

Table 3.

PI3K alterations in trastuzumab refractory lesions versus untreated HER2+ cohort

PIK3CA mutation or PTEN absent/reduced expression P value
Trastuzumab refractory cohort Primary untreated HER2+ cohort
PIK3CA 13/45 (29%, 95%CI 16–44%) 13/73 (18%, 95%CI 10–29%) .176
PTEN 33/56 (59%, 95% CI 46–71%) 25/73 (34%, 95% CI 24–46%) .007
PIK3CA or PTEN 29/41 (71%, 95% CI 54–83%) 32/73 (44%, 95% CI 32–56%) .007